Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

CSF biomarkers for Alzhei… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival

Artikel i vetenskaplig tidskrift
Författare Anders Wallin
Kaj Blennow
N. Andreasen
Lennart Minthon
Publicerad i Dement Geriatr Cogn Disord
Volym 21
Nummer/häfte 3
Sidor 131-8
ISSN 16391474
Publiceringsår 2006
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Sidor 131-8
Språk en
Länkar www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Aged, Aged, 80 and over, Alzheimer Disease/cerebrospinal fluid/*diagnosis/drug therapy/mortality, Amyloid beta-Protein/*cerebrospinal fluid, Apolipoproteins E/genetics, Biological Markers/*cerebrospinal fluid, Diagnostic and Statistical Manual of Mental Disorders, Female, Genotype, Humans, Male, Mental Status Schedule, Middle Aged, Nerve Tissue Proteins/*cerebrospinal fluid, Neuropsychological Tests, Peptide Fragments/*cerebrospinal fluid, Phosphorylation, Prognosis, Reference Values, Retrospective Studies, Risk, Statistics, Survival Analysis, Tacrine/therapeutic use, tau Proteins
Ämneskategorier Neurokemi

Sammanfattning

Cerebrospinal fluid (CSF) samples from 21 patients with a clinical diagnosis of Alzheimer's disease (AD) participating in a 5-year treatment study with the choline esterase inhibitor tacrin were retrospectively analyzed for the contents of beta-amyloid (Abeta42), total tau (T-tau) and phosphorylated tau (P-tau). A significant positive correlation between the level of P-tau and the number of symptoms according to the DSM-IV criteria (p = 0.041) and the NINCDS-ADRDA (p = 0.029) was observed (i.e. higher levels were found in cases with more symptoms). A significant positive correlation between T-tau, P-tau and ADAS-cog score was identified (i.e. higher levels were found with more severe cognitive dysfunction). Patients who died during the 5-year follow-up had significantly lower levels of Abeta42 (p = 0.011) than those who were still alive. Patients who had died in a 6-year follow-up had significantly lower levels of Abeta42 (p = 0.034) and higher levels of T-tau (p = 0.041) than patients still alive. CONCLUSION: CSF biomarkers do aid the clinical diagnosis of AD. Increased levels of P-tau and T-tau are possible markers for severity and abundance of symptoms in AD. Low levels of Abeta42 may indicate a higher risk of early death in AD.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?